KR102218883B1 - 생물활성, 나노입자포집된 항산화제의 전달 - Google Patents

생물활성, 나노입자포집된 항산화제의 전달 Download PDF

Info

Publication number
KR102218883B1
KR102218883B1 KR1020177003119A KR20177003119A KR102218883B1 KR 102218883 B1 KR102218883 B1 KR 102218883B1 KR 1020177003119 A KR1020177003119 A KR 1020177003119A KR 20177003119 A KR20177003119 A KR 20177003119A KR 102218883 B1 KR102218883 B1 KR 102218883B1
Authority
KR
South Korea
Prior art keywords
lutein
nanoparticles
composition
delete delete
surfactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177003119A
Other languages
English (en)
Korean (ko)
Other versions
KR20170097601A (ko
Inventor
크리스티나 엠. 사블리브
카롤스 이. 아스테테
에드 보도키
올리뷰 보스티라루
오비듀 치프리안 사모이라
엘레나 딘테
Original Assignee
보드 오브 슈퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬춰럴 앤드 메카니컬 컬리지 쓰루 더 엘에스유 에이쥐센터
이울이우 하티에가누 유니버시티 오브 메디신 앤드 파르마시
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 보드 오브 슈퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬춰럴 앤드 메카니컬 컬리지 쓰루 더 엘에스유 에이쥐센터, 이울이우 하티에가누 유니버시티 오브 메디신 앤드 파르마시 filed Critical 보드 오브 슈퍼바이저스 오브 루이지애나 스테이트 유니버시티 앤드 애그리컬춰럴 앤드 메카니컬 컬리지 쓰루 더 엘에스유 에이쥐센터
Publication of KR20170097601A publication Critical patent/KR20170097601A/ko
Application granted granted Critical
Publication of KR102218883B1 publication Critical patent/KR102218883B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177003119A 2014-08-11 2015-08-10 생물활성, 나노입자포집된 항산화제의 전달 Active KR102218883B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462035683P 2014-08-11 2014-08-11
US62/035,683 2014-08-11
US201562172455P 2015-06-08 2015-06-08
US62/172,455 2015-06-08
PCT/US2015/044483 WO2016025394A2 (en) 2014-08-11 2015-08-10 Delivery of bioactive, nanoencapsulated antioxidants

Publications (2)

Publication Number Publication Date
KR20170097601A KR20170097601A (ko) 2017-08-28
KR102218883B1 true KR102218883B1 (ko) 2021-02-23

Family

ID=55304745

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177003119A Active KR102218883B1 (ko) 2014-08-11 2015-08-10 생물활성, 나노입자포집된 항산화제의 전달

Country Status (12)

Country Link
US (2) US10292943B2 (https=)
EP (1) EP3179988A4 (https=)
JP (1) JP6668327B2 (https=)
KR (1) KR102218883B1 (https=)
AP (1) AP2017009684A0 (https=)
AU (1) AU2015301945B2 (https=)
BR (1) BR112017002580A2 (https=)
CA (1) CA2992879C (https=)
EA (1) EA035620B1 (https=)
MX (1) MX388028B (https=)
WO (1) WO2016025394A2 (https=)
ZA (1) ZA201700987B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388028B (es) * 2014-08-11 2025-03-19 Univ Louisiana State Suministro de antioxidantes bioactivos, nanoencapsulados.
WO2019148140A2 (en) * 2018-01-26 2019-08-01 Wu Joseph C Implantable biomaterials that enhance stem cell survival and function
CA3174213A1 (en) * 2019-06-14 2020-12-17 Daniela Oana Trambitas Method for micro-encapsulation of natural ingredients by means of contacting with supercritical gas
CA3181943A1 (en) * 2020-05-11 2021-11-18 Op2Lysis Slow release plasminogen activator formulation for use in the treatment of thrombotic or haemorrhagic disease
US11253481B1 (en) 2021-07-12 2022-02-22 King Abdulaziz University Self-nanoemulsifying 3D-printed tablet composition and method of use thereof
US11298321B1 (en) 2021-07-12 2022-04-12 King Abdulaziz University Methods for treating metabolic disorder
KR102824097B1 (ko) 2022-12-07 2025-06-24 주식회사 엘지생활건강 바이오틴이 담지된 나노파티클 및 이의 제조 방법, 및 이의 용도
WO2025106389A1 (en) * 2023-11-13 2025-05-22 Universitatea De Medicină Şi Farmacie Iluiu Haţieganu New forms of lutein and their uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386960A3 (en) 1989-03-07 1991-10-23 American Cyanamid Company Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
US6573299B1 (en) 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
US6703039B2 (en) * 2000-12-06 2004-03-09 Bausch & Lomb Incorporated Reversible gelling system for ocular drug delivery
DE10141018A1 (de) * 2001-08-22 2003-03-13 Eth Zuerich Eidgenoessische Te Verwendung von negativ geladenen Phospholipiden, sowie Zusammensetzungen umfassend Phospholipide zur Behandlung des Auges
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
EP1534202B1 (en) * 2002-06-05 2009-03-11 University Of Florida Research Foundation, Inc. Ophthalmic drug delivery system
MX2008004981A (es) * 2005-10-16 2008-10-17 Lycored Ltd Composiciones para el tratamiento de enfermedades de los ojos.
US9707185B2 (en) 2007-05-07 2017-07-18 Board Of Supervisors Of Louisana State University And Agricultural And Mechanical College Water-soluble nanoparticles containing water-insoluble compounds
BR112013000675B1 (pt) * 2010-07-16 2021-07-20 Universidad De Navarra Nanopartícula, processo para produzir uma nanopartícula compreendendo uma matriz de zeína e um aminoácido básico, composição e produto alimentar
JP5829685B2 (ja) * 2010-09-03 2015-12-09 サンテン・エス・エー・エス 眼の疾患を処置するための油中水型エマルション
BR112013021731A2 (pt) * 2011-02-25 2016-11-01 Univ South Dakota nanopartícula;composição farmacêutica ou cosmética;utilização; método para melhorar a estabilidade de um retinóide;método para melhorar a dispersibilidade de um retinóide; método para proporcinar a libertação sustentada de um retinóide; método para aumentar a penetração na pele de um retinóide;método para aumentar a acumulação de tumor de encapsulamento de droga;método para reduzir a acumulação de drogas em tecidos de rolamento não tumorais; método para reduzir a toxicidade de um retinóide;método para reduzir a irritação da pele classificação de um retinóide aplicado topicamente encapsulante compreendendo uma pluralidade de nanopartículas;método de preparação de uma nanopartícula
US20120231072A1 (en) * 2011-03-11 2012-09-13 Chemisches Institut Schaefer Ag Thermo-responsive hydrogel compositions
CN103845278B (zh) * 2012-11-30 2016-06-22 沈阳药科大学 一种叶黄素眼用纳米乳-温度敏感型原位凝胶及其制备方法
MX388028B (es) * 2014-08-11 2025-03-19 Univ Louisiana State Suministro de antioxidantes bioactivos, nanoencapsulados.

Also Published As

Publication number Publication date
ZA201700987B (en) 2019-05-29
EP3179988A2 (en) 2017-06-21
EA201790361A1 (ru) 2017-06-30
AU2015301945A1 (en) 2017-03-09
CA2992879A1 (en) 2016-02-18
CA2992879C (en) 2022-10-25
US20190254987A1 (en) 2019-08-22
MX388028B (es) 2025-03-19
US20170216221A1 (en) 2017-08-03
AP2017009684A0 (https=) 2017-01-31
AU2015301945B2 (en) 2020-05-14
EP3179988A4 (en) 2018-11-14
JP6668327B2 (ja) 2020-03-18
WO2016025394A3 (en) 2016-05-19
EA035620B1 (ru) 2020-07-16
KR20170097601A (ko) 2017-08-28
US10292943B2 (en) 2019-05-21
BR112017002580A2 (en) 2018-03-27
JP2017523983A (ja) 2017-08-24
MX2017001903A (es) 2017-09-26
WO2016025394A2 (en) 2016-02-18
US10952974B2 (en) 2021-03-23

Similar Documents

Publication Publication Date Title
KR102218883B1 (ko) 생물활성, 나노입자포집된 항산화제의 전달
Yuan et al. Fabrication and characterization of lutein-loaded nanoparticles based on zein and sophorolipid: enhancement of water solubility, stability, and bioaccessibility
Imam et al. Formulation and optimization of levofloxacin loaded chitosan nanoparticle for ocular delivery: In-vitro characterization, ocular tolerance and antibacterial activity
Bodoki et al. Topical nanodelivery system of lutein for the prevention of selenite-induced cataract
Abd-Elsalam et al. Mucoadhesive olaminosomes: a novel prolonged release nanocarrier of agomelatine for the treatment of ocular hypertension
Lopedota et al. The use of Eudragit® RS 100/cyclodextrin nanoparticles for the transmucosal administration of glutathione
CN113226293B (zh) 利用壳聚糖涂覆的纳米胶囊及其用途
Sheir et al. Chitosan alginate nanoparticles as a platform for the treatment of diabetic and non-diabetic pressure ulcers: Formulation and in vitro/in vivo evaluation
US20250332101A1 (en) Composition
JP7584421B2 (ja) 大環状ラクトン製剤、その調製方法、及び眼部寄生虫に続発する症状の治療における該製剤の使用
Taheri et al. Preparation, physicochemical, and retinal anti-angiogenic evaluation of poloxamer hydrogel containing dexamethasone/avastin-loaded chitosan-N-acetyl-L-cysteine nanoparticles
JP7390738B2 (ja) キトサンでコートされたナノカプセル及びその用途
Wong et al. A trade-off between solubility enhancement and physical stability upon simultaneous amorphization and nanonization of curcumin in comparison to amorphization alone
Shukla et al. Chitosan coated alginate micro particles for the oral delivery of antifilarial drugs and combinations for intervention in Brugia malayi induced lymphatic filariasis
Jaber et al. Preparation and evaluation of ascorbyl glucoside and ascorbic acid solid in oil nanodispersions for corneal epithelial wound healing
Shetty et al. Micelle nanogel–based drug delivery system for lutein in ocular administration
US20200000736A1 (en) Oil-free carotenoid composition
JP2003500435A (ja) 抗感染剤および／または抗炎症剤を適用するための製剤
US11318090B1 (en) In situ gelling composition as a pH-selective and mucoadhesive sustained release drug delivery system
US20160030401A1 (en) Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
KR102384243B1 (ko) 레티놀 또는 레티놀 유도체를 포함하는 키토산이 코팅된 나노캡슐 및 이의 용도
Chakraborty et al. In vivo Study of Insulin-loaded Microemulsion Topical gel with Aloe vera for the Treatment of Dermatologic Manifestation of Diabetes
KR101771483B1 (ko) 루테인의 용출률 및 안정성이 개선된 이중층 구조의 고분자 캡슐, 이의 제조방법 및 이를 함유하는 안과질환 예방 또는 치료용 약제학적 조성물
WO2025106389A1 (en) New forms of lutein and their uses
Gad et al. Employment of Squash-synthesized Nanoselenium and Chitosan as Nanocomposites for Delivering Insulin

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6